Contact usContact us

The Company

Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.

Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.

Domain Therapeutics applies a multi-string corporate strategy to grow its business through:

  • validation of its technologies through collaborative partnerships with Pharma/Biotechs,
  • generation of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS and oncology,
  • valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies.

Domain Therapeutics
Last News

19-07-08

Domain Therapeutics appoints Xavier Leroy as chief technology officer 

190708-domain-cto-eng.pdf 

16/06/24

Domain Therapeutics strengthens its scientific advisory board with leading GPCR and disease experts

190624-domain-sab-announcement-en-final.pdf 

19-06-12

Domain Therapeutics appoints Sylvie Ryckebusch to board of directors

190612-domain-sylvie-ryckebusch-en.pdf 


19-05-28

European Venture Capital Firm Seventure Partners  renews its support to Domain Therapeutics  and invests €3.5M ($3.9M) to prepare the next growth phase 

190528-domain-therapeutics-seventure-en.pdf